541 related articles for article (PubMed ID: 29907126)
1. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.
Medina DJ; Goodell L; Glod J; Gélinas C; Rabson AB; Strair RK
Haematologica; 2012 Aug; 97(8):1255-63. PubMed ID: 22371181
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Alexeeva J; Pereira J; Drach J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F;
N Engl J Med; 2015 Mar; 372(10):944-53. PubMed ID: 25738670
[TBL] [Abstract][Full Text] [Related]
4. miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.
Yuan J; Zhang Q; Wu S; Yan S; Zhao R; Sun Y; Tian X; Zhou K
Exp Hematol; 2021 Nov; 103():52-59.e2. PubMed ID: 34474146
[TBL] [Abstract][Full Text] [Related]
5. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
6. Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL.
Lim SK; Peng CC; Low S; Vijay V; Budiman A; Phang BH; Lim JQ; Jeyasekharan AD; Lim ST; Ong CK; Tan SM; Li Y
Leukemia; 2023 Feb; 37(2):441-452. PubMed ID: 36446947
[TBL] [Abstract][Full Text] [Related]
7. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
[TBL] [Abstract][Full Text] [Related]
8. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
Pham LV; Tamayo AT; Yoshimura LC; Lo P; Ford RJ
J Immunol; 2003 Jul; 171(1):88-95. PubMed ID: 12816986
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
11. Management of mantle cell lymphoma in the elderly: current and potential strategies.
Vignon M; Venon MD; Hermine O; Delarue R
Drugs Aging; 2013 Dec; 30(12):979-86. PubMed ID: 24178346
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Rahal R; Frick M; Romero R; Korn JM; Kridel R; Chan FC; Meissner B; Bhang HE; Ruddy D; Kauffmann A; Farsidjani A; Derti A; Rakiec D; Naylor T; Pfister E; Kovats S; Kim S; Dietze K; Dörken B; Steidl C; Tzankov A; Hummel M; Monahan J; Morrissey MP; Fritsch C; Sellers WR; Cooke VG; Gascoyne RD; Lenz G; Stegmeier F
Nat Med; 2014 Jan; 20(1):87-92. PubMed ID: 24362935
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Rudelius M; Rosenfeldt MT; Leich E; Rauert-Wunderlich H; Solimando AG; Beilhack A; Ott G; Rosenwald A
Haematologica; 2018 Jan; 103(1):116-125. PubMed ID: 29079592
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
Liu X; Wang B; Ma X; Guo Y
Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Saba NS; Liu D; Herman SE; Underbayev C; Tian X; Behrend D; Weniger MA; Skarzynski M; Gyamfi J; Fontan L; Melnick A; Grant C; Roschewski M; Navarro A; Beà S; Pittaluga S; Dunleavy K; Wilson WH; Wiestner A
Blood; 2016 Jul; 128(1):82-92. PubMed ID: 27127301
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
[TBL] [Abstract][Full Text] [Related]
18. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
19. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
